Assay Report
Methods · Standard Curves · QC · Results
Specialized Enzyme-Linked ImmunoSpot (ELISpot) and multi-color FluoroSpot bioanalytical testing services to evaluate the in vitro functional potency, antigen-specific activation, and cytolytic secretory capacity of CAR-T cells, TCR-T cells, NK cells, and bispecific T-cell engagers (TCEs).
By enumerating active single-cell secretion of cytotoxic effector molecules—including Granzyme B, Perforin, and IFN-γ—upon co-culture with target-expressing tumor cells down to 1 in 1,000,000 single cells, our testing platform delivers quantitative cellular potency metrics for preclinical cell therapy development.
Universal experimental design dimensions ensuring sound biological comparison and analytical specificity.
| Planning Dimension | Core Parameters Defined Collaboratively | Impact on Data Integrity & Interpretation |
|---|---|---|
| E:T Ratio Titration Curve | Multi-point Effector-to-Target titration series (e.g., 10:1, 5:1, 2.5:1, 1:1, 0.5:1) | Establishes full dose-response killing curves and calculates per-cell cytotoxic efficiency. |
| Target Cell Specificity Controls | Target-positive tumor cells (e.g., CD19+, BCMA+, HER2+) vs. target-negative isogenic parental lines | Proves strict CAR/TCR antigen-dependent cytolytic triggering and excludes non-specific background lysis. |
| Incubation Timing & Kinetics | 4–6 hours (acute cytotoxic degranulation) vs. 18–24 hours (dual Granzyme B + IFN-γ activation) | Captures primary synaptic granule release before target cell overgrowth or effector exhaustion occurs. |
| Dual Granzyme B / IFN-γ FluoroSpot | Simultaneous dual-fluorophore detection (Granzyme B-550 / IFN-γ-490) in the same well | Identifies polyfunctional cytotoxic effectors that simultaneously destroy targets and secrete Th1 cytokines. |
| Cryopreservation & Thawing QC | Post-thaw recovery resting (1–2h at 37°C) and automated viability verification (>80%) | Ensures high post-thaw CAR-T viability and prevents false-negative suppression from dead cell debris. |
Validated single-cell testing configurations across CAR-T, TCR-T, NK cell products, and bispecific antibodies.
| Therapy Modality & Application | Target Antigens & Model Systems | Primary Readout & Analytes | Dedicated Research Application |
|---|---|---|---|
| CAR-T In Vitro Potency Screening | CD19, BCMA, CD22, HER2, EGFRvIII, Claudin 18.2 | Granzyme B & IFN-γ Spot Counts (SFU) | Quantifying antigen-specific effector killing frequency and benchmarking candidate scFv binding domains. |
| TCR-T Neoantigen & TAA Cytotoxicity | NY-ESO-1, MAGE-A4, KRAS-G12D, TP53 neoepitopes | Dual Granzyme B / IFN-γ FluoroSpot | Measuring MHC-restricted target cell lysis and TCR avidity across HLA-matched tumor target lines. |
| NK Cell & CAR-NK Degranulation | K562 target cells, antibody-dependent CD16 ADCC | Perforin & Granzyme B single-cell release | Evaluating natural cytotoxicity, CAR-mediated killing, and ADCC potency across allogeneic NK cell lots. |
| Bispecific T-Cell Engager Potency | CD3-bispecifics (e.g., CD3×CD19, CD3×CD20, CD3×PSMA) | T-cell redirection Granzyme B SFU | Quantifying T-cell redirection potency and minimal active concentration in peripheral blood mononuclear cell (PBMC) / tumor co-cultures. |
| Exhaustion & Repeat-Challenge Assays | Serial antigen re-stimulation co-culture regimens | Longitudinal SFU decline curves | Assessing functional persistence, exhaustion resistance, and sustained killing capacity over time. |
Evaluating sensitivity, safety, and cellular resolution across cytotoxicity platforms.
| Technical Dimension | Granzyme B ELISpot (Our Service) | Chromium-51 ($^{51} ext{Cr}$) Release | Flow Cytometry CD107a Degranulation | Soluble LDH Release Assay |
|---|---|---|---|---|
| Primary Measurement | Single-cell cytotoxic enzyme secretion | Target membrane isotope leakage | Surface marker translocation | Bulk enzymatic leakage |
| Single-Cell Frequency Count | Yes (Direct SFU enumeration) | No (Bulk population average) | Yes (Flow percentage) | No (Bulk population average) |
| Radioactivity Hazard | None (100% Non-radioactive) | High (Strict 51Cr handling) | None | None |
| Sensitivity at Low E:T Ratios | Excellent (Detects killing at 0.5:1 E:T) | Poor (Requires 20:1 to 50:1 E:T) | Moderate (~1% limit) | Poor (Requires high cell numbers) |
| Co-Cytokine Profiling | Yes (Granzyme B + IFN-γ + Perforin) | No (Lysis only) | Yes (With intracellular cytokine staining [ICS] permeabilization) | No (Lysis only) |
| Cell Product Consumption | Minimal (10k–50k CAR-T cells/well) | High (>500,000 cells/test) | Moderate (>100,000 cells/test) | High |
Standardized operating procedures, automated spot deconvolution, and rigorous quality gating.
Tumor cell lines authenticated by STR profiling, verified mycoplasma-free, and target antigen surface expression quantified by flow cytometry prior to co-culture.
Automated spot filtering separates genuine Granzyme B secretory footprints from cellular debris, outputting normalized SFU per 10^4 or 10^5 effector cells.
Negative controls (effector alone, target alone, effector + target-negative cells <5 SFU); positive controls (anti-CD3/CD28 >500 SFU).
Controlled thawing of cryopreserved CAR-T cells and target tumor lines; viability verification (threshold >80%).
Seeding effector cells (10,000–50,000 cells/well) with target tumor cells at defined E:T ratios in PVDF plates.
Incubation for 4–6 hours (acute degranulation) or 18–24 hours (dual Granzyme B/IFN-γ) at 37°C in 5% CO2.
Cell removal, plate washing, and incubation with anti-Granzyme B and anti-IFN-γ detection antibodies.
Automated scanning on Mabtech readers, background subtraction, and delivery of normalized SFU/effector cell datasets.
Standardized pre-analytical handling protocols ensuring optimal effector cell viability and reliable cytotoxic activation.
| Pre-Analytical Parameter | Why It Matters for Cellular Therapy Potency Testing | Intake Specification & Recommendation |
|---|---|---|
| Effector Post-Thaw Viability | Cryopreservation shock and apoptotic cells release proteases that suppress immunological synapse formation. | Effector cell viability must exceed 80%; include a 1–2 hour resting phase at 37°C in complete medium. |
| Target Cell Culture Quality | Over-confluent or unhealthy target cells exhibit spontaneous lysis and inconsistent antigen presentation. | Harvest target tumor cells during logarithmic growth phase (viability >90%); verify target antigen expression. |
| Effector-to-Target (E:T) Ratio | Suboptimal ratios cause under-stimulation or spot overcrowding, preventing accurate linear quantification. | Test a 3- to 5-point E:T titration curve (e.g., 10:1, 5:1, 1:1, 0.2:1) across duplicate or triplicate wells. |
| Input Cell Quantity | Multi-target and titration testing requires adequate cell aliquots across duplicate/triplicate wells. | Provide minimum 3–5 × 10^6 cryopreserved viable CAR-T / effector cells per test condition. |
| Serum & Media Selection | Serum lot variability can influence background activation; heat-inactivation is necessary to eliminate complement. | Use pre-screened heat-inactivated FBS or human AB serum; avoid exogenous recombinant cytokines during co-culture. |
Applying Granzyme B single-cell potency testing across CAR-T lead optimization, TCR-T neoantigen avidity, and bi-specifics.
Benchmark the single-cell killing potency and activation kinetics of competing CAR construct designs against target tumor lines.
Measure Granzyme B release against tumor cells presenting mutant neoantigens (KRAS, TP53) versus wild-type controls.
Quantify lot-to-lot consistency and functional cytolytic activity across preclinical and translational cell manufacturing runs.
Evaluate T-cell redirection potency, E:T kinetics, and minimal active concentration across donor PBMC cohorts.
Measure rapid Perforin and Granzyme B secretion from engineered allogeneic NK cell products against hematologic and solid tumor targets.
Evaluate enhancement of CAR-T killing frequency upon co-administration of immune checkpoint inhibitors or small-molecule agonists.
Standardized bioanalytical documentation, annotated spot images, and senior immunologist consultation.
Key peer-reviewed publications establishing Granzyme B ELISpot as a direct surrogate for cell-mediated cytotoxicity.
Study Design Takeaway: Reviews the critical cellular potency parameters (Granzyme B, IFN-γ release) governing clinical antitumor efficacy in adoptive CAR-T therapy.
Study Design Takeaway: Demonstrates that Granzyme B ELISpot is a non-radioactive, highly sensitive direct surrogate for cell-mediated cytotoxicity, outperforming chromium release at low E:T ratios.
Study Design Takeaway: Establishes standardized validation criteria, substrate kinetics, and spot counting parameters for Granzyme B single-cell enumeration in immunotherapy.
Study Design Takeaway: Validates serial ELISpot monitoring to assess functional persistence and tumor killing capacity across longitudinal cell therapy regimens.
Addressing common project planning, cell handling, and assay selection inquiries.
Granzyme B ELISpot measures the direct enzymatic release of cytotoxic granules at the single-cell level upon tumor engagement. It is 100% non-radioactive, requires far fewer effector cells, and detects killing at low E:T ratios (e.g., 1:1 or 0.5:1) where chromium release fails.
Yes. Using our multi-color FluoroSpot configuration, Granzyme B (cytolytic release) and IFN-γ (immunomodulatory activation) are measured simultaneously in the same microplate well, resolving polyfunctional cytotoxic T cells.
Every assay includes target-negative isogenic tumor cells (or non-transduced parental lines) alongside target-positive cells. True CAR/TCR potency is confirmed only when spot counts are significantly elevated in target-positive wells over target-negative background.
Standard protocols require only 10,000 to 50,000 CAR-T cells per well. For a full E:T titration curve with target controls in triplicate, we typically recommend providing 3–5 × 10^6 cryopreserved viable effector cells.
Yes. We routinely test allogeneic NK/CAR-NK degranulation against tumor targets, as well as T-cell redirection potency mediated by bispecific antibodies in PBMC/tumor co-culture systems.
No. All bioanalysis services provided by Creative Proteomics are strictly for Research Use Only (RUO). They are intended for preclinical discovery, in vitro potency characterization, lead optimization, and translational research cohorts, and are not intended for clinical diagnostic or patient management procedures.
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×